# DESCRIPTION

## TECHNICAL FIELD

## BACKGROUND ART

## DISCLOSURE OF INVENTION

## MODES FOR CARRYING OUT THE INVENTION

### Section A: Peptide Vaccines

### Section B: Conjugate Vaccines

## Reagents and General Methods

### Fmoc-Lys(ivDde)-NovasynTG

### H-YGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(ivDde)-NovasynTG

### AcYGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(SATA)-OH (Compound 1)

### HS(CH2)2CO-YGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(SATA)-OH (Compound 2)

### βMan3-S(CH2)2CO-YGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(SATA)-OH (Compound 4)

### Conjugation of the Peptides AcYGKDVKDLFDYAQE(SEQ ID NO:1)-TEG-K(SATA)-OH and βMan3-S(CH2)2CO-YGKDVKDLFDYAQE(SEQ ID NO: 1)-TEG-K(SATA)-OH to Tetanus Toxoid

